MATE Act Training to Fulfill DEA Application and Renewal Process

David Neff, DO; David Best, DO, Pamela Lynch, LMSW, CAADC

Meet the new 8-hour training requirement on demand!

The Michigan Osteopathic Association (MOA) and Michigan Health & Hospital Association (MHA) have teamed up to offer Medication Access and Training Expansion (MATE) Act training requirements on demand for the treatment and management of patients with opioid and other substance use disorders and to meet the Drug Enforcement Administration’s (DEA) one-time, eight-hour training requirement for all DEA registered practitioners.

Effective on June 27, 2023: All DEA-registered and new medical practitioners are required to attest to the completion of the training when renewing or completing an initial registration.

This course qualifies for 9.25 AOA Category 1-A Credits and 9.25 AMA PRA Category 1 Credit(s)TM. The DEA training is available for purchase in the online learning center, and individual modules are also offered.   

Registration Rates
MOA & MHA Members $149
Non-Members $199
Group discount offered for multiple providers from the same organization:

  • 5-25, $125 per Provider
  • 26-50, $100 per Provider
  • 51-100, $75 per Provider

Please contact MOA for rates for more than 100 providers.

CME Accreditation

The Michigan Osteopathic Association is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. The Michigan Osteopathic Association designates this program for a maximum of 9.25 AOA Category 1-A Credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity. Upon course completion, MOA will submit credits to AOA.

MyMichigan Health is accredited by the Michigan State Medical Society (MSMS) to provide continuing medical education for physicians. MyMichigan Health designates this live activity for a maximum of 9.25 AMA PRA Category 1 Credit(s)™. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MyMichigan Health and Michigan Osteopathic Association. Upon course completion, an EEDS link will be provided for MD credit submission.

Physicians have the option to register for full course,that fulfills the DEA requirements, or individual modules. Take advantage of MOA and MHA discount member and group rates by registering at:

New DEA Training Requirement Takes Effect June 27

Who Is Impacted, Eligible Training, and Attestation
As mandated by the federal Medication Access and Training Expansion (MATE) Act of 2021, beginning June 27, 2023, prescribers of controlled substances in schedules II, III, IV, and V must complete a one-time eight-hour training on managing patients with substance use disorders prior to their first registration or renewal of their Drug Enforcement Agency license.

This means the eight-hour training requirement must be met before:

  • Applying for a DEA license for the first time on/after June 27, 2023; or
  • One’s next DEA license renewal date on/after June 27, 2023.

This is a one-time DEA requirement. Once you’ve attested to completing eight hours of required training, you will not need to complete additional training for subsequent DEA renewals. It is important to note that for medical licensure in Michigan, physicians must still obtain three hours of training on pain and symptom management every 3-year licensure cycle.

DEA letter to Registered-Practitioners
Provider Clinical Support System: Requirements for training for Medication Assistant Treatment as part of the MATE Act

Questions or comments for the Safe Opioid Task Force

The MOA established the Safe Opioid Task Force in 2015. The Task Force works to advocate on behalf of physicians and the patients they serve on the issues of preventing addiction, treating addiction, and providing information on safe prescribing guidelines.

Questions or Comments
If you have questions, comments or concerns regarding the information being shared, please use this form. Your submission will be forwarded to members of the Task Force. The time is takes to reply may  depend on the issue. 

Safe Opioid Task Force Question/Comment form

Proposed CDC Clinical Practice Guideline for Prescribing Opioids - Public Comments are being accepted

Proposed CDC Clinical Practice Guideline for Prescribing Opioids–United States, 2022 that can be found in the following URL within the Federal Register - Federal Register :: Proposed 2022 CDC Clinical Practice Guideline for Prescribing Opioids. This update provides key revisions from the 2016 version, particularly for those who have chronic disease that incites severe intractable and largely incurable pain. 

Prescribing Opioids—United States, 2022 (the clinical practice guideline). The clinical practice guideline updates and expands the CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016, and provides evidence-based recommendations for clinicians who provide pain care, including those prescribing opioids, for outpatients age 18 years and older with acute pain (duration less than 1 month), subacute pain (duration of 1-3 months), or chronic pain (duration of 3 months or more), not including sickle cell disease-related pain management, cancer pain treatment, palliative care, and end-of-life care. The clinical practice guideline includes recommendations for primary care clinicians (including physicians, nurse practitioners, and physician assistants) as well as for outpatient clinicians in other specialties (including those managing dental and post-surgical pain in outpatient settings and emergency clinicians providing pain management for patients being discharged from emergency departments). This voluntary clinical practice guideline provides recommendations and does not require mandatory compliance; and the clinical practice guideline is intended to be flexible so as to support, not supplant, clinical judgment and individualized, patient-centered decision-making.

CDC Clinical Practice Guideline for Prescribing Opioids
2016 vs. 2022 CDC Opioid Guideline comparison (PDF) from the U.S. Pain Foundation

 5 Strategic Pillars to Combat opioid abuse

The Michigan Osteopathic Association (MOA) has developed a strategy for combating the opioid crisis facing Michigan. The MOA's "5 Strategic Pillars" were developed based on recommendations from the MOA Presidential Task Force on Safe Opioid Use, the Michigan Governor's Task Force and The Office of the White House.

On this page, you will find news and info about efforts from the MOA and around Michigan to lessen the burden of the opioid epidemic, a full cadre of resources and useful links for both providers and patients and a section on the MOA Presidential Task Force on Safe Opioid Use.

Goal - reduce opioid-related deaths and morbidity, while we treat patients with pain and/or addiction with compassion and expertise.
Click here for the 5 Strategic Pillars


There are many online resources available to learn more about the opioids issue in Michigan. The MOA has compiled some web links for you.

Safe Drug Disposal Information for Michigan

Providers' Clinical Support System For Opioid Therapies

Balancing Pain Management and Prescription Opioid Abuse

Opioid painkiller prescribing varies widely among states

Prescription Painkiller Overdoses

Prescription Painkiller Overdoses in the US

Gov. Rick Snyder forms task force to address prescription drug and opioid problems in Michigan

MAPS Report 2014- (PDF)

America's Addiction to Opioids: Heroin and Prescription Drug Abuse

Prescription Opioid and Heroin Abuse 

Incidence of Neonatal Abstinence Syndrome — 28 States